New Sotyktu Commercial for Plaque Psoriasis: Living Life Without a “Filter”
XTalks
JUNE 10, 2024
Sotyktu (deucravacitinib) is a one-of-its-kind oral medication approved by the US Food and Drug Administration (FDA) indicated to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a sentiment that heavily resonates within the psoriasis community.
Let's personalize your content